← Back to Clinical Trials
Recruiting NCT06327906

NCT06327906 A Prospective Birth Cohort of Infants With Allergy and Neurodevelopmental Disorders in China

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06327906
Status Recruiting
Phase
Sponsor Qilu Hospital of Shandong University
Condition Child Allergy
Study Type OBSERVATIONAL
Enrollment 6,000 participants
Start Date 2023-11-15
Primary Completion 2026-11-15

Eligibility & Interventions

Sex All sexes
Min Age 1 Minute
Max Age 42 Days
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 6,000 participants in total. It began in 2023-11-15 with a primary completion date of 2026-11-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study, a birth cohort was established to demonstrate the causal relationship between allergies and neurodevelopment disorders in infants and young children, and to find out the influencing factors of neurodevelopment disorders in early life.

Eligibility Criteria

Inclusion Criteria: * ①Allergic questionnaire results were positive. * The living area is Jinan City and its surrounding areas in Shandong Province, which is convenient for follow-up. Exclusion Criteria: * There is a clear diagnosis of brain developmental disorders * Psychological diseases * History of craniocerebral trauma or brain organic disease ④Major physical diseases ⑤Visual and auditory disorders ⑥ Epilepsy ⑦Intellectual disabilities

Contact & Investigator

Central Contact

cao aihua, post-doctoral

✉ xinercah@163.com

📞 18560086317

Principal Investigator

cao aihua, post-doctoral

PRINCIPAL INVESTIGATOR

Qilu Hospital of Shandong University

Frequently Asked Questions

Who can join the NCT06327906 clinical trial?

This trial is open to participants of all sexes, aged 1 Minute or older, up to 42 Days, studying Child Allergy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06327906 currently recruiting?

Yes, NCT06327906 is actively recruiting participants. Contact the research team at xinercah@163.com for enrollment information.

Where is the NCT06327906 trial being conducted?

This trial is being conducted at Jinan, China.

Who is sponsoring the NCT06327906 clinical trial?

NCT06327906 is sponsored by Qilu Hospital of Shandong University. The principal investigator is cao aihua, post-doctoral at Qilu Hospital of Shandong University. The trial plans to enroll 6,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology